NurExone Biologic Inc.
NRXBF
$0.48
$0.000.00%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.35% | 41.77% | 43.54% | 43.01% | 48.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.23% | 52.61% | 52.69% | 49.97% | 36.90% |
| Operating Income | -26.23% | -52.61% | -52.69% | -49.97% | -36.90% |
| Income Before Tax | -26.59% | -54.35% | -52.58% | -50.35% | -38.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.59% | -54.35% | -52.58% | -50.35% | -38.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.59% | -54.35% | -52.58% | -50.35% | -38.54% |
| EBIT | -26.23% | -52.61% | -52.69% | -49.97% | -36.90% |
| EBITDA | -24.56% | -50.95% | -51.71% | -49.37% | -36.54% |
| EPS Basic | -3.54% | -20.47% | -11.04% | -3.88% | 4.23% |
| Normalized Basic EPS | -3.23% | -20.44% | -11.04% | -4.08% | 3.88% |
| EPS Diluted | -3.54% | -20.47% | -11.04% | -3.88% | 4.23% |
| Normalized Diluted EPS | -3.23% | -20.44% | -11.04% | -4.08% | 3.88% |
| Average Basic Shares Outstanding | 24.50% | 29.79% | 35.46% | 41.06% | 42.30% |
| Average Diluted Shares Outstanding | 24.50% | 29.79% | 35.46% | 41.06% | 42.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |